Psychedelic therapy provider Mindbloom said that its guided at-home ketamine therapy was found safe and effective in a peer-reviewed study.
The therapy is a telehealth-supported ketamine treatment for depression.
The research findings were published in the Journal of Affective Disorders, authored by psychiatrists and researchers affiliated with Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom.
It assessed data from 11,441 Mindbloom clients, making it the most extensive evaluation of ketamine therapy to date.
According to the results, 62% of clients reported clinically significant improvements in depression or anxiety, with 28% achieving remission.
The trial also showed significant symptom improvements after just four sessions.
Additionally, less than 5% of clients reported adverse effects.
Furthermore, 84% of clients who initially experienced significant improvements maintained or recovered those gains in a subsequent round of treatment.
Mindbloom founder and CEO Dylan Beynon said: “Mindboom’s programmes make ketamine therapy accessible and affordable, allowing people to heal from the comfort of home.
“People have questioned whether ketamine therapy could be delivered safely and effectively at home through telehealth – this study answers that question with an emphatic ‘yes’.”
The trial’s authors said that Mindbloom’s comprehensive support, which includes 1:1 coaching, therapeutic content, and group integration, plays a crucial role in enhancing the effectiveness and safety of the treatment.
In addition, the firm’s at-home ketamine therapy programs address barriers like cost, provider availability, and stigma that prevent people from accessing effective mental health care.
This is also second peer-reviewed study on Mindbloom’s clinical outcomes. It validates and expands upon the findings of their initial study with a sample size ten times larger.
It introduces new insights into the advantages of ongoing ketamine therapy beyond the initial treatment phase.
Furthermore, the study employed artificial intelligence (AI) and machine learning tools to identify predictive factors for treatment response.
In November last year, the psychedelic therapy provider introduced its Mastermind Series, a psychedelic therapy programmes for heartbreak, burnout, and other mental health issues.
